Loading
Life sciences · Journal article
Frontiers in Pharmacology · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Glucagon like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the management of T2D and obesity. T2D clustering highlights distinct phenotypes that differ in GLP-1RA benefit. While they have markedly improved quality of life for many individuals, converging evidence indicates that genetic variation, metabolomic remodeling, and gut microbiota composition contribute to substantial inter-individual variability in GLP-1RA efficacy and tolerability. GLP-1RAs, in return, can variably affect the metabolome and microbiome composition in treated individuals. This review focuses on human multi-omics GLP-1RA intervention studies, complemented by relevant mechanistic preclinical evidence. Genetic variation in GLP1R, TCF7L2, and other loci has been associated with differences in glycaemic and weight outcomes, although most findings remain preliminary, inconsistent across populations, or not yet replicated. Pharmacometabolomic studies show recurrent of lipid-related pathways including, glycerophospholipids, sphingolipids, ceramides, amino acids, and bile acids, with drug-specific signatures. GLP-1RAs are also associated with changes in gut microbial composition, including taxa such as Akkermansia and Bacteroides, although the direction and clinical significance of these changes vary across studies due to methodological and population heterogeneity. Multi-omics and AI-based models show promise for predicting treatment response by integrating genetic, metabolic, microbial, and clinical data to supporting more effective and individualized therapy and advancing precision medicine.